Year: 2020
Type: review
Abstract: Liver-related diseases are the third-leading causes (9.3%) of mortality in type 2 diabetes (T2D) in Japan. T2D is closely associated with nonalcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to hepatocellular carcinoma (HCC) and hepatic failure. No pharmacotherapies are established for NASH patients with T2D. Though vitamin E is established as a first-line agent for NASH without T2D, its efficacy for NASH with T2D recently failed to be proven. The effects of pioglitazone on NASH histology with T2D have extensively been established, but several concerns exist, such as body weight gain, fluid retention, cancer incidence, and bone fracture. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and NAFLD (LEAN study, LEAD trial, and E-LIFT study). Among a variety of SGLT2 inhibitors, dapagliflozin has already entered the phase 3 trial (DEAN study). A key clinical need is to determine the kinds of antidiabetic drugs that are the most appropriate for the treatment of NASH to prevent the progression of hepatic fibrosis, resulting in HCC or liver-related mortality without increasing the risk of cardiovascular or renal events. Combination therapies, such as glucagon receptor agonist/GLP-1 or gastrointestinal peptide/GLP-1, are under development. This review focused on antidiabetic agents and future perspectives on the view of the treatment of NAFLD with T2D.
DOI: 10.3390/ijms21061907
Authors: Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono, Yuichi Nozaki, Hideyuki Hyogo, Masahiro Koseki, Yuichi Yoshida, Takumi Kawaguchi, Yoshihiro Kamada, Takeshi Okanoue, Atsushi Nakajima, Japan Study Group of NAFLD (JSG-NAFLD)
Institutions: Aichi Medical University, Yokohama City University, Tokyo Women's Medical University, Institute of Gastroenterology, Tokyo Women's Medical University, Kawasaki Medical School, Osaka City University, Saga University, National Center for Global Health and Medicine, Hiroshima General Hospital, The University of Osaka, Suita Municipal Hospital, Kurume University, Saiseikai Suita Hospital
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,112
Awards: Elucidation of the relationship between focal cirrhosis and hepatocellular carcinoma in nonalcoholic steatohepatitis, An exploration for biomarkers for predicting heart failure prognosis by the human olfactory-based odor analysis technology, Development of NAFLD patient prognosis prediction method using glycan biomarkers and elucidation of its biological significance, Development of therapeutic drug for steatohepatitis by liver-specific bio-nanocapsules equipped with RNAi targeting TTC39B
OpenAlex ID: W3011655835
